This could explain how patients with nephrotic syndrome carrying MC1R mutations impairing cAMP response can benefit from ACTH treatment23, by still having intact ERK1/2 signaling downstream of the MC1R. The gene discussed is MAPK3; the disease is nephrotic syndrome.